The pharmaceutical industry in Uzbekistan is set to undergo significant changes following the implementation of new regulations outlined in the Decree of the President of the Republic of Uzbekistan, URetail reported. The new decree, which comes into force on July 1, 2024, aims to enhance compliance monitoring, control drug advertisements, and foster growth and innovation within the sector.
Enhanced compliance monitoring
One of the key provisions of the decree is the introduction of a compliance monitoring procedure for organizations involved in the manufacturing, wholesale, and retail sale of medicines and medical products. These organizations will now be required to notify the authorized body, except for control measures based on individual and legal entity requests, no more than once a year. This measure ensures that the license requirements issued to these organizations are strictly adhered to, promoting quality and safety standards across the industry.
Controlled drug advertisements
In a move to regulate the advertising of medicines and dietary supplements, the Ministry of Health will now issue conclusions determining the content to be broadcast on television and radio channels. Advertisements for pharmaceutical products will be subject to the scrutiny of the Ministry, ensuring that the information disseminated to the public is accurate, reliable, and in compliance with industry guidelines. This step aims to protect consumers from misleading or false claims, promoting responsible marketing practices within the pharmaceutical sector.
Financial commitment to drive innovation and growth
President Mirziyoyev's decree emphasizes a significant financial commitment to stimulate innovation and foster growth within the pharmaceutical industry. A substantial budget of up to $600mn has been allocated to finance new investment projects, forming a crucial part of this ambitious initiative.
Follow Daryo's official Instagram and Twitter pages to keep current on world news.
Comments (0)